Carrying over the “bect” in its logo as a nod to Becton, Dickinson and Company, embecta will maintain international manufacturing sites that previously produced around 8 billion injection devices ...
BD’s new company will have the freedom to expand its portfolio of tools and technologies for the chronic care of diabetes. (BD) () After nearly a century spent building out its portfolio of insulin ...
Standalone Diabetes Care business expected to leverage position as global leader in insulin delivery and expand presence in large and high-growth diabetes market - Spinoff allows both BD and NewCo to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results